Breaking News, Trials & Filings

Xeloda Combo Approved for Early Colon Cancer

Roche’s Xeloda (capecitabine) in combination with oxaliplatin (a combination known as XELOX) has been approved by the EMEA for the adjuvant treatment of patients with early colon cancer.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Roche’s Xeloda (capecitabine) in combination with oxaliplatin (a combination known as XELOX) has been approved by the EMEA for the adjuvant treatment of patients with early colon cancer. The approval was based on results from the NO16968 (XELOXA) study in patients with stage III (early) colon cancer, which showed that patients taking XELOX after surgery lived disease free for longer compared to those treated with chemotherapy regimen 5-fluorouracil/leucovorin (5-FU/LV). “The approval of...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters